

# Inovio and Regeneron announce a clinical study for a immuno-oncology trial

[Inovio Pharmaceuticals, Inc. \(NASDAQ: INO\)](#) and [Regeneron Pharmaceuticals, Inc. \(NASDAQ: REGN\)](#) today announced a clinical study agreement for a phase 1b/2a immuno-oncology trial.

The study will be conducted by Inovio in patients with newly diagnosed glioblastoma multiforme (GBM) and will evaluate Regeneron's PD-1 inhibitor, REGN2810, in combination with Inovio's INO-5401 T cell activating immunotherapy encoding multiple antigens and INO-9012, an immune activator encoding IL-12.





